NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 84 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5 | -99.9% | 10,365 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | -68.2% | 10,365 | -52.0% | 0.00% | – |
| Q2 2022 | $22,000 | -46.3% | 21,583 | 0.0% | 0.00% | – |
| Q1 2022 | $41,000 | -71.1% | 21,583 | -26.7% | 0.00% | – |
| Q4 2021 | $142,000 | -15.0% | 29,443 | +27.2% | 0.00% | – |
| Q3 2021 | $167,000 | -51.3% | 23,142 | -37.7% | 0.00% | – |
| Q2 2021 | $343,000 | +90.6% | 37,145 | +153.4% | 0.00% | – |
| Q1 2021 | $180,000 | -94.8% | 14,658 | -94.0% | 0.00% | -100.0% |
| Q4 2020 | $3,432,000 | -8.9% | 243,396 | -22.5% | 0.00% | -50.0% |
| Q3 2020 | $3,767,000 | -45.3% | 313,962 | -24.3% | 0.00% | -33.3% |
| Q2 2020 | $6,882,000 | +41.8% | 414,564 | -2.8% | 0.00% | 0.0% |
| Q1 2020 | $4,853,000 | -10.4% | 426,493 | -3.0% | 0.00% | +50.0% |
| Q4 2019 | $5,418,000 | +379.5% | 439,800 | +10.9% | 0.00% | – |
| Q3 2019 | $1,130,000 | – | 396,417 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
| ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
| EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
| Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
| Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
| Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
| Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
| Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
| PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
| Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |